Document is current
Any future updates will be listed below
-
Authors
Cao, Guoshuai
Hu, Yifei https://orcid.org/0000-0003-2870-7772
Pan, Tony https://orcid.org/0000-0001-9115-0650
Tang, Erting
Asby, Nicholas
Althaus, Thomas
Wan, Jun https://orcid.org/0000-0001-9286-6562
Riedell, Peter A.
Bishop, Michael R.
Kline, Justin P.
Huang, Jun https://orcid.org/0000-0003-0271-4384
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (5UL1TR002389-02)
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 16 April 2025
First Online: 6 May 2025
Competing interests
: P.A.R. reports Research Support/Funding: BMS, Kite Pharma, Inc./Gilead, MorphoSys, Calibr, Tessa Therapeutics, Fate Therapeutics, Xencor, and Novartis Pharmaceuticals Corporation. Speaker’s Bureau: Kite Pharma, Inc./Gilead; Consultancy on advisory boards: AbbVie, Novartis Pharmaceuticals Corporation, BMS, Janssen, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, Kite Pharma, Inc./Gilead, Sana Biotechnology, Nektar Therapeutics, Nurix Therapeutics, Intellia Therapeutics, and Bayer. Honoraria: Novartis Pharmaceuticals Corporation. M.R.B. reports Membership on an Advisory Board or Consultancy for Kite/Gilead, Novartis, CRISPR Therapeutics, Autolus Therapeutics, BMS, Incyte, Sana Biotechnology, Iovance Biotherapeutics. He has served on a Speakers Bureau for BMS, Kite/Gilead, Agios, and Incyte. J.P.K. receives research support from Merck, Verastem, and iTeos; has served on a speaker’s bureau for Kite/Gilead; and has served on advisory boards for Verastem, Seattle Genetics, MorphoSys, and Karyopharm. The remaining authors declare no competing interests.
